|
Klaus Fiebig founded KMFBio
Inc. in 2013 to support biotech and life science
consulting efforts with emphasis on:
High value disease areas; agriculture and
environment
Advanced life science technologies, bio-informatics,
and genomics
Fundraising and grant writing support for large
projects, consortia, and centres
Business planning and strategy development for
industry, biotech, and entrepreneurs
Dr. Fiebig founded KMFBio Inc. with 14 years of
leadership experience across industry (5 years),
academia (2 years), and the non-for-profit sector (7
years):
CSO & VP of Research
Programs at the Ontario Genomics Institute (OGI),
Toronto. Dr. Fiebig led OGI's program
management team and was responsible for its research
project portfolio of 60+ large scale projects valued at
more than CAD $800 Million. He cultivated relations with
academic institutions, principal investigators, and
external funding sources, and managed OGI's efforts to
support new project development.
Senior Director of
Structural Biology and Computational Chemistry at Affinium
Pharmaceuticals, Toronto. Led Affinium's
structural biology and computational chemistry teams and
was responsible for supporting internal antibiotic drug
discovery programs. Dr. Fiebig also directed a 20-person
strategic alliance with Pfizer
valued at $30 Million US that focused on structural
proteomics and structure-based drug discovery of more than
50 anti-infective targets.
Co-founder and CEO of
MRPharm GmbH, Frankfurt. MRPharm was a biotech
startup with focus on NMR-based drug discovery which was
spun out of a joint academic-industry drug discovery
project between the University of Frankfurt
and Aventis Pharma which
was led by Dr. Fiebig. Prior to MRPharm Dr. Fiebig was
a lead scientist with Xencor
Inc., Los Angeles, responsible for improving
Xencor's computational platform for protein design.
|
